4 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Terminated 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow pegcetacoplan: new trials by email Literature Review of pegcetacoplan trials Research Report on pegcetacoplan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safely Quenching Complement in Stroke Survivors Pegcetacoplan Injection [Empaveli] - Acute Ischemic Stroke, Cerebral Infarction | Phase 1 | Not yet recruiting | Columbia University | 20 | 2026-10-01 | 2026-04-29 |
| Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 35 | 2026-02-16 | 2026-08-19 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) RO7669330, Syfovre™, Izervay™ - Geographic Atrophy, Age-related Macular Degeneration | Phase 1 | Terminated | Hoffmann-La Roche | 27 | 2025-07-16 | 2026-11-04 |
| Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy PEGCETACOPLAN (APL-2) - Geographic Atrophy | Phase 1 | Completed | Apellis Pharmaceuticals, Inc. | 19 | 2018-11-05 | 2021-11-10 |
| Pegcetacoplan (APL-2) in Neovascular AMD Pegcetacoplan - Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | Terminated | Apellis Pharmaceuticals, Inc. | 17 | 2018-02-14 | 2020-09-16 |
| Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Apellis Pharmaceuticals, Inc. | 23 | 2015-12-01 | 2021-01-11 |
| A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH Pegcetacoplan - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 | Completed | Apellis Pharmaceuticals, Inc. | 9 | 2015-02-23 | 2021-01-08 |
| Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD Pegcetacoplan - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Apellis Pharmaceuticals, Inc. | 13 | 2015-01-28 | 2020-10-06 |
Anemia (2) · Geographic Atrophy (2) · Hematologic Diseases (2) · Hemoglobinuria (2) · Hemoglobinuria, Paroxysmal (2) · Hemolysis (2) · Cerebral Infarction (1) · Ischemic Stroke (1) · Macular Degeneration (1) · Pancreatic Neoplasms (1) · Reperfusion Injury (1) · Thromboinflammation (1)
Apellis Pharmaceuticals, Inc. (5) · Columbia University (1) · Hoffmann-La Roche (1) · Roswell Park Cancer Institute (1)
United States (6) · Australia (1) · Hong Kong (1) · Malaysia (1) · New Zealand (1) · Thailand (1)
Federico Grossi, MD, PhD (3) · Christos Fountzilas (1) · E Sander Connolly, MD (1) · Federico Grossi, MD PhD (1)